<DOC>
	<DOCNO>NCT01363986</DOCNO>
	<brief_summary>This single-arm , multicenter , open-label study evaluate efficacy safety Herceptin ( trastuzumab ) combination whole brain radiotherapy brain metastases patient HER-2 positive breast cancer . The patient receive Herceptin 4 mg/kg ( load dose ) follow 2 mg/kg maximum 18 weekly cycle . The anticipated time study treatment 18 week .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Combination With Whole Brain Radiotherapy Patients With HER-2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Diagnosis breast carcinoma HER2 overexpression At least one measurable brain metastasis Patients , accord investigator assessment , whole brain radiotherapy best therapeutic option Performance status ( WHO ) &lt; /=2 Life expectancy &gt; /=3 month Presence neoplastic meningitis Any prior radiotherapy brain Patients , accord investigator assessment , stereotactic radiotherapy best therapeutic option Previous neoplasm , breast carcinoma , within 5 year since enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>